Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.040
-0.160 (-7.27%)
Oct 10, 2025, 2:50 PM EDT - Market open
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$3,988,765
Market Cap
67.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | 14 | 8 | 133.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RLMD News
- 3 days ago - Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - GlobeNewsWire
- 24 days ago - Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Relmada Issues Mid-Year CEO Letter to Shareholders - GlobeNewsWire
- 2 months ago - Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC - GlobeNewsWire
- 2 months ago - Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 - GlobeNewsWire
- 3 months ago - DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors - GlobeNewsWire